StarHorizon recognized as "Industry Benchmark for Full-Chain Commercialization Landing Services of Chinese Pharmaceutical Enterprises in Southeast Asia"! The special summit concluded successfully, empowering a new journey for traditional Chinese medicine going global.

Created on Today

Introduction

On August 1, the 2026 Practical Analysis Session on Chinese Patent Medicine Expansion into Southeast Asia, hosted by Xinghan Biotechnology Co., Ltd. and co-organized by the China Federation of Logistics & Purchasing Pharmaceutical Logistics and Supply Chain Branch, concluded successfully.

This forum abandons vague industry theories, focusing on the pain points of the entire commercialization chain for Chinese traditional medicine pharmaceutical companies expanding into Southeast Asia. It brings together frontline experts in industry research, overseas pharmaceutical compliance, cross-border operations, and foreign-related law to deliver a full set of practical, actionable insights. On-site, it jointly released an industry white paper with iiMedia Research and unveiled the benchmark enterprise rankings. Xinghan Bio also secured a special authoritative market position certification, using data and practical strength to solidify its leading position in the full-chain services for traditional Chinese medicine going overseas to Southeast Asia.

1. Industry Leaders Gather, Four Practical Themes Decode the Full Process of Going Overseas

This special session fully covers the entire cycle of pharmaceutical companies going overseas, from market research, compliance access, commercial operations, to cross-border risk control. The four keynote speeches progress layer by layer, solving the core challenges enterprises face in expanding abroad.

1. Leadership Address, Anchoring the Development Direction of Traditional Chinese Medicine Internationalization

Guo Wei, Executive Deputy Secretary-General of the Medical Logistics and Supply Chain Branch of the China Federation of Logistics & Purchasing, took the stage first to deliver a speech, offering professional guidance and development expectations for the traditional Chinese medicine Southeast Asia expansion track from the perspectives of pharmaceutical supply chain internationalization and industry standardization.

Liu Weimin, Vice President of Xinghan Bio, delivered a welcome speech, sharing Xinghan's original intention and layout in deeply cultivating Southeast Asia for many years and building a full-chain service system for Chinese pharmaceutical companies' commercialization in Southeast Asia, while also extending a sincere welcome to all attending pharmaceutical executives and industry peers.

2. Four Hardcore Practical Sharing Sessions, Directly Targeting Industry Pain Points

1. Comprehensive Analysis of the Southeast Asian Market

Bian Jiaqi, Deputy Director of the Research Office of the Pharmaceutical Logistics and Supply Chain Branch of the China Federation of Logistics and Purchasing, thoroughly analyzed the consumption habits, epidemic characteristics, regulatory patterns, and channel models of various Southeast Asian countries, accurately identifying potential markets for pharmaceutical companies going overseas.

2. Multi-country drug registration compliance pitfalls avoidance guide

Singapore Oasis Bio Regulatory Director Lee Yung Jen provides an in-depth interpretation of filing rules across Southeast Asian countries including Singapore HSA, Indonesia BPOM, Thailand TFDA, and Vietnam DAV, with the physical handbook "Overseas TCM Registration Compliance Guide" distributed on-site to help companies avoid time and capital losses in going global.

3. New Approaches to Commercial Operations in Southeast Asia

Liu Weimin, Vice President of Xinghan Bio, combines years of hands-on case experience to compare cooperation models such as wholly-owned, joint venture, and local distribution binding, breaking down the replicable underlying business logic of channel building, profit distribution, and risk allocation.

4. Legal Risk Prevention and Control for Cross-Border Transactions

Gu Yang, Partner at Han Kun Law Offices, shares insights on cross-border cooperation contracts, overseas intellectual property protection, and cross-border commercial dispute resolution, building a solid legal moat for companies going global.

2. Major Release | Joint Launch of Industry White Paper with iiMedia, Standardized Ranking System Unveiled

The second half of the achievement ceremony features the most anticipated segment of the entire event.

Leveraging the strength of iiMedia Consulting as a leading domestic third-party industry research platform, Xinghan Bio, together with Dr. Zhang Yi, founder of iiMedia Consulting, officially released the "2026 China TCM Going Global White Paper" on-site.

At the release event, Dr. Zhang Yi fully explained the underlying logic of the ranking selection:

✅ Five core evaluation indicators: revenue scale, depth of overseas layout, localization operation capability, compliance level, and brand influence

✅ Clear delineation of screening criteria, data sources, and participating enterprises scope

✅ Comprehensive analysis of the regional distribution and mainstream business models of listed enterprises

✅ In-depth commentary on representative benchmark enterprise cases in the sector

After the complete interpretation, the list of benchmark enterprises for Traditional Chinese Medicine going overseas in 2026 will be officially announced on-site, providing practical and referenceable examples for domestic pharmaceutical companies going abroad.

An exclusive material collection channel will be opened on-site: attendees can go to the registration desk, follow the official WeChat account of Xinghan Bio, and receive a free copy of the '2026 China Traditional Chinese Medicine Going Overseas White Paper' and the Southeast Asia Registration Compliance Guide physical manual; for needs related to going overseas in Southeast Asia, project cooperation, compliance consulting, etc., attendees can also consult the staff at the registration desk for one-on-one professional services.

III. Honor and Glory | Xinghan awarded 'Benchmark for the Full Chain of Commercialization Services for Chinese Pharmaceutical Companies in Southeast Asia'

The most glorious award presentation segment of this forum has been officially revealed. This third-party authoritative certification by iiMedia Consulting breaks through the general definition of the Traditional Chinese Medicine going overseas sector, focusing exclusively on the full chain of commercialization service field for Chinese pharmaceutical companies in Southeast Asia, ultimately awarding Xinghan Bio the title of 'Benchmark for the Full Chain of Commercialization Services for Chinese Pharmaceutical Companies in Southeast Asia', backed by authoritative data, recognizing Xinghan's benchmark strength and industry-leading value in one-stop overseas service.

1. Dr. Zhang Yi from iiMedia Consulting explained on-site the complete selection criteria and multi-dimensional evaluation system for this certification, providing in-depth commentary on Xinghan Bio's forward-looking layout and unique industry value in the Traditional Chinese Medicine going overseas sector in Southeast Asia;

2. The host guided the audience to watch the brand development VCR of Xinghan Bio, intuitively showcasing the company's development process in deeply cultivating Southeast Asia and building a one-stop overseas full chain service;

3. After the VCR playback, the big screen switched to the exclusive award presentation page, and Dr. Zhang Yi went on stage to present the certification plaque to Mr. Chen Shiping of Xinghan Bio, with both parties taking a commemorative photo.

Unlike generalized industry honor awards, this 'Benchmark for the Full Chain of Commercialization Services for Chinese Pharmaceutical Companies in Southeast Asia' special certification precisely anchors Xinghan Bio's core service advantages: covering overseas market research, multi-country drug compliance registration, local channel operational implementation, cross-border business cooperation, and legal risk control in a complete closed loop. It is an authoritative affirmation of Xinghan's deep cultivation in the practical sector of Southeast Asia, standardized commercialization services, and empowering domestic traditional Chinese medicine brands to go abroad steadily, officially establishing the company's benchmark position in the field of commercialization services for Traditional Chinese Medicine in Southeast Asia.

IV. Based on practical experience, continuously build a service hub for the Traditional Chinese Medicine going overseas industry

The full 4-hour special session completes the complete knowledge map for going global from four dimensions: market, compliance, operations, and legal, supplemented by three major industry achievements including white papers, benchmark rankings, and third-party authoritative certifications, providing objective data references and practical implementation models for the entire industry.

After the official agenda concludes, a free business networking and matchmaking area opens on-site, where numerous pharmaceutical company representatives, industry experts, and service providers exchange resources and discuss in-depth cooperation for Southeast Asian expansion.

Event Highlights

About Xinghan Bio

Xinghan Biotechnology Co., Ltd. focuses on providing full-chain services for Chinese pharmaceutical companies in Southeast Asian expansion and commercialization. Integrating overseas compliance registration, local distribution channels, industry data research, and cross-border legal supporting resources, it offers one-stop Southeast Asian market entry and implementation solutions for Chinese patent medicine enterprises.

In the future, Xinghan Bio will continue to build a professional exchange platform for TCM internationalization, deliver a standardized, low-cost, and highly implementable overseas expansion service system, accompany more quality domestic Chinese patent medicine brands to take root in Southeast Asia, achieve long-term commercial growth, and promote the two-way export of China's TCM industry and culture.